Immunic, Inc.
IMUX
$12.32
$0.131.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.61% | 29.80% | 17.99% | 16.10% | 10.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.99% | 8.56% | 5.28% | 10.16% | 12.41% |
| Operating Income | -11.99% | -8.56% | -5.28% | -10.16% | -12.41% |
| Income Before Tax | -9.55% | -8.19% | 3.32% | -6.34% | -6.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.55% | -8.19% | 3.32% | -6.34% | -6.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.55% | -8.19% | 3.32% | -6.34% | -6.85% |
| EBIT | -11.99% | -8.56% | -5.28% | -10.16% | -12.41% |
| EBITDA | -12.02% | -8.56% | -5.25% | -10.13% | -12.37% |
| EPS Basic | 55.59% | 43.10% | 31.84% | 32.54% | 37.41% |
| Normalized Basic EPS | 56.52% | 44.02% | 29.25% | 29.75% | 35.30% |
| EPS Diluted | 55.59% | 43.10% | 31.84% | 32.54% | 37.41% |
| Normalized Diluted EPS | 56.52% | 44.02% | 29.25% | 29.75% | 35.30% |
| Average Basic Shares Outstanding | 155.96% | 103.11% | 55.22% | 53.33% | 51.35% |
| Average Diluted Shares Outstanding | 155.96% | 103.11% | 55.22% | 53.33% | 51.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |